EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer

Marina Z Jovanović, Milena Jurišević, Milan Jovanović, Nevena Gajović, Miodrag Jocić iD, Marina M Jovanović iD, Boško Milev, Krstina Doklestić Vasiljev, Ivan Jovanović iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marina Z Jovanović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Mammary Neoplasms, Experimental, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Immunological, Interleukin-1 Receptor-Like 1 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia under Grant Agreements with University of Kragujevac-Faculty of Medical Scien…, Medical faculty of Military Medical Academy, Ministry of Science, Technological Development and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in immunotherapy, the treatment of breast cancer still remains a major global problem. In a previous study, we showed that co-blockade of Interleukin-33/ST2 and Programmed death-1/Programmed death-ligand (PD-1/PD-L) signaling pathways strongly slows progression by enhancing the antitumor capacity of natural killer (NK) cells. The main aim of this study is to elucidate the exact effect of co-blockade on the T lymphocyte and macrophage effector cells. 4T1 cells were used to induct breast cancer in female BALB/C and BALB/C ST2−/− mice. The mice, both BALB/C and BALB/C ST2−/−, were treated with anti-PD-1 antibody on certain days. After the mice were sacrificed, T cells and macrophages were analyzed using flow cytometry; dual co-blockade increased significantly the percentage of M1 macrophages in the tumor microenvironment, followed by an increase in expression of CD86+ and TNFα+. T cell accumulation was significantly higher in the spleen and within the tumor microenvironment, with elevation in activation markers such as Interleukin-17, CD69, NKG2D, and FasL and a decrease in Interleukin-10 and FoxP3 expression. Co-blockade of the PD-1/PD-L axes and IL-33/ST2 axes shows promising results in reestablishing an effective immune response and offers a new perspective on improving immune response to breast carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mammary Neoplasms, ExperimentalProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Antineoplastic Combined Chemotherapy ProtocolsMice, Inbred BALB CTumor MicroenvironmentCell Line, TumorFemaleAnimalsMiceMice, KnockoutT-LymphocytesSignal TransductionMacrophages

Stichwörter der Autor:innen

IL-33T cellsanti-PD-1breast cancermacrophages

Substanzen

Pdcd1 protein, mouseProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalIl33 protein, mouseIl1rl1 protein, mouseInterleukin-1 Receptor-Like 1 ProteinInterleukin-33

Autor:innen und Institutionen

  • Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Otorhinolaryngology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia.
  • Medical Faculty of the Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
  • Institute for Transfusiology and Haemobiology, Military Medical Academy, 11000 Belgrade, Serbia.

ORCID-Profile: Miodrag Jocić, Marina M Jovanović, Ivan Jovanović

Förderung

  • Ministry of Science, Technological Development and Innovation, Republic of Serbia under Grant Agreements with University of Kragujevac-Faculty of Medical Scien…
  • Medical faculty of Military Medical Academy
  • Ministry of Science, Technological Development and Innovation

Zitieren

APA

Jovanović, M. Z., Jurišević, M., Jovanović, M., Gajović, N., Jocić, M., Jovanović, M. M., Milev, B., Vasiljev, K. D., & Jovanović, I. (2025). Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199600

Vancouver

Jovanović MZ, Jurišević M, Jovanović M, Gajović N, Jocić M, Jovanović MM, et al. Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199600

BibTeX
@article{Jovanovi2025,
  author = {Jovanović, Marina Z and Jurišević, Milena and Jovanović, Milan and Gajović, Nevena and Jocić, Miodrag and Jovanović, Marina M and Milev, Boško and Vasiljev, Krstina Doklestić and Jovanović, Ivan},
  title = {Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199600}
}
Kostenlos starten →